Senti Biosciences Holdings, Inc. (SNTI)
| Market Cap | 29.75M |
| Revenue (ttm) | 22,000 |
| Net Income (ttm) | -61.44M |
| Shares Out | 31.14M |
| EPS (ttm) | -2.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 201,490 |
| Open | 1.000 |
| Previous Close | 1.060 |
| Day's Range | 0.940 - 1.000 |
| 52-Week Range | 0.770 - 4.950 |
| Beta | 2.12 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+789.77%) |
| Earnings Date | May 6, 2026 |
About SNTI
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SNTI stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 789.77% from the latest price.
News
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences Holdings Transcript: Leerink Global Healthcare Conference 2026
Logic gating and gene circuits enable selective cancer cell targeting in AML, with SENTI-202 showing a 42% CR/CRh rate, strong safety, and rapid hematopoietic recovery in phase I. RMAT designation supports a single-arm registrational trial, and expansion into new indications and modalities is planned.
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences Holdings Transcript: TD Cowen 46th Annual Health Care Conference
Logic-gated cell therapy SENTI-202 showed high response rates and deep, durable remissions in relapsed/refractory AML, with a favorable safety profile and broad patient eligibility. Plans are underway for a pivotal trial and expansion into new indications, with strong physician and regulatory interest.
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 int...
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
Access the segment here
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Biosciences Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Biosciences Holdings Transcript: Study Update
Senti 202, an off-the-shelf logic-gated CAR-NK therapy, showed a 50% ORR and 42% CR/CRh rate with high MRD negativity and excellent safety in heavily pretreated relapsed/refractory AML patients. The therapy's unique NOT gate mechanism preserves healthy cells, supporting rapid recovery and broad applicability.
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical eviden...
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Biosciences Holdings Transcript: Chardan’s 9th Annual Genetic Medicines Conference
SENTI-202, a logic-gated CAR NK cell therapy, demonstrated promising safety and efficacy in relapsed/refractory AML, with high response rates and MRD negativity. The platform is expanding to solid tumors and will present more robust data on ~20 patients by year-end.
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Bio to Present at BioJapan
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Biosciences Holdings Transcript: MedInvest Biotech & Pharma Conference
SENTI-202, an off-the-shelf logic-gated NK cell therapy for AML, demonstrated strong safety and efficacy in phase 1, with 57% complete remission and 100% MRD-negative responses. Additional data and pipeline expansion are expected by year-end.
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...